In SOD1 and TDP43 animal models of ALS there is evidence of complement activation (119, 120), and genetic deficiency or pharmacological inhibition of the C5a receptor, C5aR1, is protective in rodent SOD1G93A models (73, 121–123). Here, TARDBP is linked to amyotrophic lateral sclerosis.